Free Access
Med Sci (Paris)
Volume 23, Number 12, Décembre 2007
Page(s) 1073 - 1074
Section Éditorial
Published online 15 December 2007
  1. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344 : 1084–6. [Google Scholar]
  2. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib : randomised trial. Lancet 2004; 364 : 1127–34. [Google Scholar]
  3. McArthur G. Molecularly targeted treatment for dermatofibrosarcoma protuberans. Semin Oncol 2004; 31(suppl 6) : 30–6. [Google Scholar]
  4. Blay JY, Le Cesne A, Ray-Coquard I, et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year : the French Sarcoma Group. J Clin Oncol 2007; 25 : 1107–13. [Google Scholar]
  5. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350 : 2335–42. [Google Scholar]
  6. Yang JC, Haworth L, Sherry RM, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349 : 427–34. [Google Scholar]
  7. Slamon DJ, Leyland-Jones B, Shak S. Use of chemotherapy plus a monoclonal antibody against HER2 for mstatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344 : 783–92. [Google Scholar]
  8. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313 : 1960–4. [Google Scholar]
  9. Borg C, Terme M, Taieb J, et al. Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects. J Clin Invest 2004; 114 : 379–88. [Google Scholar]
  10. Charafe-Jauffret E, Chaffanet M, Bertucci F, et al. Les cancers du sein : vers un modèle cellulaire et moléculaire intégré. Med Sci (Paris) 2007; 23 : 626–32. [Google Scholar]
  11. Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006; 42 : 1093–103. [Google Scholar]
  12. Romond EH, Perez EA, Bryant J, et al Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353 : 1673–84. [Google Scholar]
  13. Smith I, Procter M, Gelber RD, et al. Two-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer : a randomised controlled trial. Lancet 2007; 369 : 29–36. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.